SIRT3 and diffuse large B-cell lymphoma: With SJ-106C, whichhas improved SIRT3 inhibition potency and aqueous solubility, we nextinvestigated whether it can inhibit the proliferation of DLBCL celllines such as the previously reported SIRT3 inhibitor YC8-02.